Disease

Developmental and epileptic encephalopathy, 59

Late-stage therapeutic development

Also known as DEE59, EIEE59, developmental and epileptic encephalopathy 59, epileptic encephalopathy, early infantile, 59+1 more

DEE59, EIEE59, developmental and epileptic encephalopathy 59, epileptic encephalopathy, early infantile, 59, infantile epileptic encephalopathy 59.

Clinical trials

Associated genes

Related proteins

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Moderate

Key developments

6 clinical trials expected to report results, the earliest in Q1 2027.

Upcoming Milestones

Major developments

Major trial resultsHigh impact

Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients

Results posted2026-06-08

Major trial resultsHigh impact

Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor

Results posted2026-06-03

Clinical Milestones14View all 14

Results posted 2

2026-06-08Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET PatientsResults posted
2026-06-03Treatment for Very Low and Standard Risk Favorable Histology Wilms TumorResults posted

Results expected 5

2026-07-10Phase III Randomized Trial of Immunotherapy With or Without Consolidative Radiotherapy for Oligometastatic Head and Neck Squamous Cell CarcinomaResults expected Q1 2029
2026-07-09A MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE LONG-TERM SAFETY AND TOLERABILITY OF BRIVARACETAM IN STUDY PARTICIPANTS WITH CHILDHOOD ABSENCE EPILEPSY OR JUVENILE ABSENCE EPILEPSYResults expected Q4 2029
2026-07-02A Phase III Randomized Trial of Eribulin (NSC #707389) With Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 TherapyResults expected Q3 2030
2026-07-02Randomized Trial of Consolidation Targeted Adjuvant Therapy With Encorafenib and Cetuximab Versus Usual Care for Patients With Stage II/III BRAF V600E Colon CancerResults expected Q2 2034
2026-01-07Phase II/III Second-Line NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM)Results expected Q1 2029

Recently completed 4

Other updates 2

+6 more in the activity timeline below

Activity timeline14

2027-02-01ClinicalIdentification, Assessment, and Treatment of Tardive Dyskinesia With Valbenazine in Adults With Intellectual/Developmental Disabilities and Co-occurring Psychiatric and/or Behavioral DisordersWithdrawn
2026-07-10ClinicalPhase III Randomized Trial of Immunotherapy With or Without Consolidative Radiotherapy for Oligometastatic Head and Neck Squamous Cell CarcinomaResults expected Q1 2029
2026-07-09ClinicalA MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE LONG-TERM SAFETY AND TOLERABILITY OF BRIVARACETAM IN STUDY PARTICIPANTS WITH CHILDHOOD ABSENCE EPILEPSY OR JUVENILE ABSENCE EPILEPSYResults expected Q4 2029
2026-07-02ClinicalA Phase III Randomized Trial of Eribulin (NSC #707389) With Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 TherapyResults expected Q3 2030
2026-07-02ClinicalRandomized Trial of Consolidation Targeted Adjuvant Therapy With Encorafenib and Cetuximab Versus Usual Care for Patients With Stage II/III BRAF V600E Colon CancerResults expected Q2 2034
2026-06-17ClinicalA Multicenter, Randomized, Double-Blind, Positive-Controlled, Cross-Over Phase Ⅲ Clinical Trial Evaluating the Efficacy and Safety of HRS-9231 for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)Completed
2026-06-10ClinicalA Multicenter Open-Label Extension Study to Evaluate the Long-Term Safety of Cenobamate Adjunctive Therapy in Subjects With Primary Generalized Tonic-Clonic SeizuresCompleted
2026-06-09ClinicalA Multicenter, Randomized, Double-Blind, Positive-Controlled, Cross-Over Phase III Clinical Trial Evaluating the Efficacy and Safety of HRS-9231 for Body Parts (Non-Central Nervous System) Magnetic Resonance Imaging (MRI)Completed
2026-06-08ClinicalEfficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET PatientsResults posted
2026-06-03ClinicalTreatment for Very Low and Standard Risk Favorable Histology Wilms TumorResults posted

Clinical trials

14 sponsors · 3 new · 6 completed in the last 12 months (net +2)

The current development programme across all trial phases.

Clinical programme

All trials

Active

Late-stage

Completed

Late-stage studies

Randomized Trial of Consolidation Targeted Adjuvant Therapy With Encorafenib and Cetuximab Versus Usual Care for Patients With Stage II/III BRAF V600E Colon Cancer

Phase 2/3 · Active, not recruiting · Alliance for Clinical Trials in Oncology

A Phase III Randomized Trial of Eribulin (NSC #707389) With Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy

Phase 3 · Active, not recruiting · National Cancer Institute (NCI)

Phase III Randomized Trial of Immunotherapy With or Without Consolidative Radiotherapy for Oligometastatic Head and Neck Squamous Cell Carcinoma

Phase 3 · Active, not recruiting · ECOG-ACRIN Cancer Research Group

Phase II/III Second-Line NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM)

Phase 2/3 · Active, not recruiting · Alliance for Clinical Trials in Oncology

A MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE LONG-TERM SAFETY AND TOLERABILITY OF BRIVARACETAM IN STUDY PARTICIPANTS WITH CHILDHOOD ABSENCE EPILEPSY OR JUVENILE ABSENCE EPILEPSY

Phase 3 · Active, not recruiting · UCB Biopharma SRL

Effect of Different Anesthetic Drugs on Electrocorticography (ECOG), Randomized Controlled Double-blinded Study

Phase 3 · Active, not recruiting · Children's Cancer Hospital Egypt 57357

Recently completed

A Multicenter, Randomized, Double-Blind, Positive-Controlled, Cross-Over Phase Ⅲ Clinical Trial Evaluating the Efficacy and Safety of HRS-9231 for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)

Phase 3 · Completed · Shanghai Shengdi Pharmaceutical Co., Ltd

A Multicenter Open-Label Extension Study to Evaluate the Long-Term Safety of Cenobamate Adjunctive Therapy in Subjects With Primary Generalized Tonic-Clonic Seizures

Phase 3 · Completed · SK Life Science, Inc.

A Multicenter, Randomized, Double-Blind, Positive-Controlled, Cross-Over Phase III Clinical Trial Evaluating the Efficacy and Safety of HRS-9231 for Body Parts (Non-Central Nervous System) Magnetic Resonance Imaging (MRI)

Phase 3 · Completed · Shanghai Shengdi Pharmaceutical Co., Ltd

A Proof-of-concept Clinical Study to Evaluate the Impact of a Combination Nutraceutical Kit on Muscle Function, Cognitive Performance, and Immune Resilience in Older Adults.

Phase 4 · Completed · GPLIFE HEALTHCARE PRIVATE LIMITED

Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients

Phase 3 · Completed · Children's Oncology Group

Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor

Phase 3 · Completed · Children's Oncology Group

Associated genes

1 match

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

GABBR20.73

Disease biology

1 match

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

Gamma-aminobutyric acid type B receptor subunit 2via GABBR20.73

Reference

Authoritative identity, definition & identifiers.

Synonyms

DEE59, EIEE59, developmental and epileptic encephalopathy 59, epileptic encephalopathy, early infantile, 59, infantile epileptic encephalopathy 59

References & data sources

Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
Related entities are derived from literature co-mention (studied together) — associative, not causal.